ERBB2 and breast cancer: Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer is the most prevalent subtype of metastatic breast cancer, accounting for over 70% of cases globally (Siegel et al., 2025; NCI, 2025; Howlader et al., 2014).